Unlocking the value of Real-World Data in the era of Gen AI

Healthcare and life sciences organizations are recognizing the value of the health data they generate. This data has both internal benefits, such as understanding patient outcomes and prescriber behavior, and external benefits, as an asset to support life sciences partners. And factors like the emergence of Generative AI models, complex clinical development programs, FDA guidance, and shifts towards value-based delivery are increasing the demand for this data. 

Investments in infrastructure and interoperability have allowed healthcare providers to accumulate high-quality, multi-modal, longitudinal Real-World Data (RWD). Early adopters are leveraging this data to drive innovation and pursue industry partnerships, setting themselves apart from competitors. They are also leveraging this data to advance patient-centered care initiatives, with a clear focus on uncovering insights that improve outcomes.

The rise of GenAI is providing new opportunities for healthcare and life sciences organizations to analyze and share data insights. However, unlocking the full potential of RWD and avoiding risks requires a clear and cohesive approach. This paper looks to examine the emerging impact of GenAI on the RWD landscape and help Healthcare and life sciences organizations unlock the value of their data.